Lazard Asset Management
ALXN

Lazard Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Lazard Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-21,267
Closed -$3.91M – 2355
2021
Q2 		$3.91M Buy
21,267
+594
+3% +$102K ﹤0.01% 755
2021
Q1 		$3.16M Buy
20,673
+7,312
+55% +$1.13M ﹤0.01% 727
2020
Q4 		$2.09M Sell
13,361
-184
-1% -$23.6K ﹤0.01% 790
2020
Q3 		$1.55M Sell
13,545
-207
-2% -$22.3K ﹤0.01% 759
2020
Q2 		$1.54M Sell
13,752
-16,066
-54% -$1.71M ﹤0.01% 713
2020
Q1 		$2.68M Buy
29,818
+10,899
+58% +$1.07M ﹤0.01% 623
2019
Q4 		$2.04M Buy
18,919
+17,643
+1,383% +$1.89M ﹤0.01% 670
2019
Q3 		$124K Sell
1,276
-12
-0.9% -$1.35K ﹤0.01% 968
2019
Q2 		$168K Buy
1,288
+1,276
+10,633% +$164K ﹤0.01% 1050
2019
Q1 		$1K Hold
12
– – ﹤0.01% 1137
2018
Q4 		$1K Hold
12
– – ﹤0.01% 1016
2018
Q3 		$1K Hold
12
– – ﹤0.01% 1043
2018
Q2 		$1K Hold
12
– – ﹤0.01% 1022
2018
Q1 		$1K Sell
12
-44
-79% -$5.26K ﹤0.01% 1031
2017
Q4 		$6K Buy
56
+33
+143% +$4.02K ﹤0.01% 1005
2017
Q3 		$3K Buy
23
+11
+92% +$1.49K ﹤0.01% 955
2017
Q2 		$1K Hold
12
– – ﹤0.01% 1003
2017
Q1 		$1K Hold
12
– – ﹤0.01% 1007
2016
Q4 		$1K Hold
12
– – ﹤0.01% 986
2016
Q3 		$1K Hold
12
– – ﹤0.01% 982
2016
Q2 		$1K Buy
12
+6
+100% +$851 ﹤0.01% 1030
2016
Q1 		$0 Hold
6
– – ﹤0.01% 1134
2015
Q4 		$1K Buy
+6
New +$1.05K ﹤0.01% 1094
2014
Q2 		– Sell
-1,200
Closed -$182K – 1079
2014
Q1 		$182K Buy
+1,200
New +$191K ﹤0.01% 832

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Lazard Asset Management's ALXN Position: Q3 2021 in Review

Lazard Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 21,267 shares — an estimated $3.91M sold.

Lazard Asset Management first reported a position in ALXN in Q1 2014 and held it in 24 quarters. The position peaked at $3.91M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Lazard Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Lazard Asset Management sold 21,267 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.91M.
  • Lazard Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 24 quarters.
  • Lazard Asset Management's Alexion Pharmaceuticals position peaked at $3.91M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Lazard Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.